Recent research have focused on the overlap of glucagon-like peptide-1|GIP|GCGR agonist therapies and DA signaling. While GCGR agonists are increasingly employed for treating type 2 diabetes mellitus, their potential effects on reinforcement circuits, specifically influenced by dopaminergic pathways, are receiving substantial attention. This art… Read More